TYRA Overview

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).

Wall Street analysts forecast TYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TYRA is33.75 USD with a low forecast of 30.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tyra Biosciences Inc revenue for the last quarter amounts to -42.00M USD, increased 31.86

Tyra Biosciences Inc. EPS for the last quarter amounts to -32659000.00 USD, increased 28.22

Tyra Biosciences Inc (TYRA) has 87 emplpoyees as of June 18 2026.

Today TYRA has the market capitalization of 1.73B USD.